Audit: QRS - Black Chokeberry for Health & Longevity

Audit conducted on 13/10/2026 15:28 using AI4L + evidence-mcp / Wonder 1.0

Iterations

Summary

Items Count
Total 94
Passed 88
Failed 0
N/A 6
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All QRS statements trace to ER Conclusion, Expected Benefits, Risks, Protocol and Monitoring passages.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Hedged wording is retained, e.g. ‘remain possible’ (QRS line 433) and ‘No established target’ (QRS lines 584-631).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No ER caution is upgraded or downgraded; pooled result is stated as ‘no clear overall benefit’ (QRS line 433), matching ER Conclusion.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Benefits, risks, contraindications and interactions stay in their ER categories (QRS lines 518-565, 534-548).
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PubMed IDs, NCT numbers, study names or brand names appear in QRS body content.
1.6 The QRS does not introduce new attributions. 🟢 No attribution beyond the ER is introduced.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Wording mirrors the ER’s restrained, inconsistent-evidence framing.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Plain, factual wording throughout the sheet.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Studied amounts and measures are presented without prescriptive instruction.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Footer states ‘Not medical advice’ (QRS lines 667-670); no advice phrasing in body.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Content is presented as studied amounts, tiers and measures, not recommendations.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address anywhere in the QRS.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 At-a-glance uses plain terms (QRS line 433); body labels are the ER’s own benefit/marker names.
2.8 Information is presented in a concise and very compact manner 🟢 Single-sheet compact layout with short tier lists and tables.
2.9 It DOES NOT address the reader directly 🟢 No direct reader address anywhere in the QRS.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing is health- and longevity-oriented (QRS lines 417, 433).
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol and monitoring detail suits proactive, effort-willing readers.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 No general-population simplification or contrary framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Benefit/risk weighting follows the ER Conclusion for this audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 Uses ‘Longevity’/’longevity-related’ (QRS lines 417, 433); ‘anti-aging’ does not appear.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 No colloquial route/clinical terms such as ‘pill’ or ‘shot’ appear.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings, gate headings, tier labels and Marker/Target/Why headers match (QRS lines 440, 477, 519, 537, 543, 554, 568, 573-575, 643).
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All template spans are present, with marker_# and qualitative_item_# correctly expanded to numbered spans (QRS lines 21-660).
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Non-checklist spans (website spans, footer, styles) are unchanged from the template.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No top-level ER section is empty; empty benefit/risk tiers are governed by items 12.5/13.5.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 QRS labels reuse ER bold labels, e.g. ‘Extract amounts studied’, ‘Juice amount studied’, ‘Timing’ (ER Protocol; QRS lines 444-466).
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Marker and tier labels copy ER wording verbatim (QRS lines 523-529, 581-631, 647-659).
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji characters appear in the QRS.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content fits the one-page template budget: three protocol cells, three time cells, five markers, five qualitative items.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment is the first element after <!doctype html> (QRS lines 1-14).
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 YAML block is delimited by — lines at QRS lines 3 and 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Metadata sits inside an HTML comment and renders nowhere on the sheet.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values are trimmed; the only quoted value, duration, contains a colon (QRS lines 4-12).
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename at QRS line 4 matches the ER frontmatter filename.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.10.8 at QRS line 5 matches QRS.md version.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-1013-1520 at QRS line 6 follows YYYY-MMDD-HHMM.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Wonder at QRS line 7.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 Nickname is the single word ‘Wonder’ (QRS line 7).
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Wonder 1.0 at QRS line 8.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 Full name is nickname plus version only: ‘Wonder 1.0’.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename at QRS line 9 matches the audited file name.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values are trimmed; the only quoted value, duration, contains a colon (QRS lines 4-12).

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 page_title is canonical_topic plus ‘ - Quick Reference Sheet’, entity-encoded (QRS line 22).
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 header_topic equals ER canonical_topic, entity-encoded (QRS line 417).
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 header_subline_date 10/13/2026 reformats qrs_creation_date (QRS line 421).
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 header_subline_model is ‘Wonder 1.0’ (QRS line 425).
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only template title and subline (QRS lines 415-428).

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens with what the fruit is and its forms/uses before any verdict (QRS line 433).
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses ER Conclusion: individual-trial signals, pooled null result, few harms (QRS line 433).
7.3 [at_a_glance] is no longer than 70 words 🟢 57 words, within the 70-word limit.
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each statement maps to ER Conclusion/Motivation passages.
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms or specialist classifications; ‘thinking speed’ and ‘blood-vessel function’ are plain terms.
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years, sample sizes or p-values.
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No effect sizes or statistical results.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from ER ‘Populations who should avoid’ under Key Interactions & Contraindications.
8.2 [stop_items] represent the Contraindications from the ER 🟢 Three stop items match the ER avoid list (QRS line 539).
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each stop item is an <li> element (QRS line 539).
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Items are bare facts with no trailing rationale or dash clauses (QRS line 539).
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 The surgery/platelet-active qualifier from the ER is preserved (QRS line 539).
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢 No ranking notation is carried into the items.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 ER identifies avoid populations and the section is populated accordingly.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not left empty: [stop_items] lists three items at QRS line 539.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from ER Key Interactions & Contraindications bullets.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Six caution items match ER interactions and none duplicates a contraindication (QRS line 545).
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each caution item is an <li> element (QRS line 545).
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Items carry no trailing explanations or dash clauses (QRS line 545).
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists from ER bullets are preserved in parentheses (QRS line 545).
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢 No ranking notation is carried into the items.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 ER identifies interactions and the section is populated accordingly.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not left empty: [caution_items] lists six items at QRS line 545.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Derived from ER Therapeutic Protocol amounts and timing.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Three action cells cover extract amounts, juice/powder amounts and timing (QRS lines 441-474).
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A ER Protocol names more than three distinct actionable aspects and all three action sets are used (QRS lines 441-474).
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All action label/value/sub spans carry ER-derived content (QRS lines 441-474).

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Time cells cover vascular, psychomotor and metabolic aspects from ER trial durations (QRS lines 480-514).
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Medium-tier vascular and psychomotor effects precede Low-tier metabolic markers.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A ER provides at least three time-to-effect aspects and all three time sets are used (QRS lines 480-514).
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All time label/value/sub spans carry ER-derived content (QRS lines 480-514).
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information (ER Practical Considerations and trial durations), so the removal condition does not apply.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Derived from ER Expected Benefits tiers.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 benefits_high/medium/low/speculative spans are used as specified (QRS lines 521-530).
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Benefit items are bare names with no sizes, qualifiers or citations (QRS lines 523-529).
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parenthetical content is retained in benefit items.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high is empty with display:none, as no High benefit exists in the ER (QRS line 521).

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Derived from ER Potential Risks & Side Effects tiers.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 risks_high/medium/low/speculative spans are used as specified (QRS lines 556-563).
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Risk items are bare names with no frequencies or citations (QRS lines 559-562).
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parenthetical content is retained in risk items.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_high and risks_medium are empty with display:none, matching the ER (QRS lines 556-557).

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Derived from ER Monitoring Protocol & Defining Success table.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All five ER biomarkers are listed (QRS lines 579-633).
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 monitoring_cadence states baseline, 8-12 week repeat and 6-12 month interval (QRS line 638).

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Derived from ER qualitative markers under Monitoring.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five ER qualitative markers are listed (QRS lines 647-659).

Issues 13/10/2026 15:28

Pass rate 100.00%. No issues found.

Issues 13/10/2026 15:25

  1. 1.1 — Dose trials misstated: QRS action_1_sub at line 450 states “Separate trials used 90 mg, 150 mg, or 500 mg daily”; the ER Therapeutic Protocol states 90 mg and 150 mg were separate groups in the single Ahles et al. cognition trial, with 500 mg in a separate trial.
  2. 4.2 / 4.3 — Protocol labels not verbatim: QRS action labels at lines 444 and 455 read “Extract amount studied” and “Juice or powder studied”; the ER bold labels are “Extract amounts studied”, “Higher extract amount studied”, “Juice amount studied”, and “Whole-fruit powder studied”.

    Fixes 13/10/2026 15:25

  3. 1.1 — Dose trials misstated: Changed action_1_sub from “Separate trials used 90 mg, 150 mg, or 500 mg daily” to “90 mg and 150 mg as separate groups; 500 mg in a separate trial”.
  4. 4.2 / 4.3 — Protocol labels not verbatim: Changed action_1_label to “Extract amounts studied / Higher extract amount studied” and action_2_label to “Juice amount studied / Whole-fruit powder studied”, using the ER bold labels verbatim.

Issues 13/10/2026 15:22

  1. 1.1 — Studied doses stated as range: QRS line 447 states “90–500 mg daily”; ER lines 284–285 studied only discrete 90 mg, 150 mg, and 500 mg daily doses, so intermediate doses are implied but untested.
  2. 12.5 — Empty High benefits placeholder: QRS lines 521–523 hide the High tier but retain the literal placeholder “[benefits_high]” instead of empty content.
  3. 13.5 — Empty risk tiers placeholder: QRS lines 558–563 hide the High and Medium tiers but retain the literal placeholders “[risks_high]” and “[risks_medium]” instead of empty content.

Fixes 13/10/2026 15:22

  1. 1.1 — Studied doses stated as range: Changed Action 1 value from “90–500 mg daily” to “90 mg, 150 mg, or 500 mg daily” to match the discrete doses studied in the ER.
  2. 12.5 — Empty High benefits placeholder: Emptied the hidden benefits_high span, removing the literal “[benefits_high]” placeholder while keeping display:none.
  3. 13.5 — Empty risk tiers placeholder: Emptied the hidden risks_high and risks_medium spans, removing the literal “[risks_high]” and “[risks_medium]” placeholders while keeping display:none.